Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
Overall Study	STARTED	Telbivudine 600 mg	116
Overall Study	STARTED	Lamivudine 100 mg	116
Overall Study	Safety Population	Telbivudine 600 mg	115
Overall Study	Safety Population	Lamivudine 100 mg	116
Overall Study	Intent to Treat (ITT) Population	Telbivudine 600 mg	114
Overall Study	Intent to Treat (ITT) Population	Lamivudine 100 mg	114
Overall Study	Completed Week 52	Telbivudine 600 mg	97
Overall Study	Completed Week 52	Lamivudine 100 mg	94
Overall Study	Completed Week 104	Telbivudine 600 mg	70
Overall Study	Completed Week 104	Lamivudine 100 mg	62
Overall Study	COMPLETED	Telbivudine 600 mg	64
Overall Study	COMPLETED	Lamivudine 100 mg	60
Overall Study	NOT COMPLETED	Telbivudine 600 mg	52
Overall Study	NOT COMPLETED	Lamivudine 100 mg	56

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00076336/flow